Public Health Ontario, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Clin Microbiol Infect. 2023 Mar;29(3):302-309. doi: 10.1016/j.cmi.2022.12.006. Epub 2022 Dec 9.
COVID-19 and antimicrobial resistance (AMR) are two intersecting global public health crises.
We aimed to describe the impact of the COVID-19 pandemic on AMR across health care settings.
A search was conducted in December 2021 in WHO COVID-19 Research Database with forward citation searching up to June 2022.
Studies evaluating the impact of COVID-19 on AMR in any population were included and influencing factors were extracted. Reporting of enhanced infection prevention and control and/or antimicrobial stewardship programs was noted.
Pooling was done separately for Gram-negative and Gram-positive organisms. Random-effects meta-analysis was performed.
Of 6036 studies screened, 28 were included and 23 provided sufficient data for meta-analysis. The majority of studies focused on hospital settings (n = 25, 89%). The COVID-19 pandemic was not associated with a change in the incidence density (incidence rate ratio 0.99, 95% CI: 0.67-1.47) or proportion (risk ratio 0.91, 95% CI: 0.55-1.49) of methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci cases. A non-statistically significant increase was noted for resistant Gram-negative organisms (i.e. extended-spectrum beta-lactamase, carbapenem-resistant Enterobacterales, carbapenem or multi-drug resistant or carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii, incidence rate ratio 1.64, 95% CI: 0.92-2.92; risk ratio 1.08, 95% CI: 0.91-1.29). The absence of reported enhanced infection prevention and control and/or antimicrobial stewardship programs initiatives was associated with an increase in gram-negative AMR (risk ratio 1.11, 95% CI: 1.03-1.20). However, a test for subgroup differences showed no statistically significant difference between the presence and absence of these initiatives (p 0.40).
The COVID-19 pandemic may have hastened the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. But there is considerable heterogeneity in both the AMR metrics used and the rate of resistance reported across studies. These findings reinforce the need for strengthened infection prevention, antimicrobial stewardship, and AMR surveillance in the context of the COVID-19 pandemic.
COVID-19 和抗菌素耐药性(AMR)是两个相互交叉的全球公共卫生危机。
我们旨在描述 COVID-19 大流行对医疗保健环境中 AMR 的影响。
2021 年 12 月在世界卫生组织 COVID-19 研究数据库中进行了检索,并进行了前瞻性引文检索,检索截止日期为 2022 年 6 月。
纳入评估 COVID-19 对任何人群中 AMR 影响的研究,并提取影响因素。注意报告增强的感染预防和控制以及/或抗菌药物管理计划。
分别对革兰氏阴性和革兰氏阳性菌进行汇总。进行了随机效应荟萃分析。
在筛选出的 6036 项研究中,有 28 项研究被纳入,其中 23 项研究提供了足够的数据进行荟萃分析。大多数研究都集中在医院环境(n=25,89%)。COVID-19 大流行与耐甲氧西林金黄色葡萄球菌或万古霉素耐药肠球菌病例的发生率密度(发病率比 0.99,95%CI:0.67-1.47)或比例(风险比 0.91,95%CI:0.55-1.49)均无变化。耐革兰氏阴性菌(即,扩展谱β-内酰胺酶、耐碳青霉烯肠杆菌科、碳青霉烯类或多药耐药或碳青霉烯类耐药铜绿假单胞菌或鲍曼不动杆菌)的发生率呈非统计学意义上的增加(发病率比 1.64,95%CI:0.92-2.92;风险比 1.08,95%CI:0.91-1.29)。未报告增强的感染预防和控制以及/或抗菌药物管理计划举措与革兰氏阴性 AMR 的增加相关(风险比 1.11,95%CI:1.03-1.20)。但是,亚组差异检验显示,这些举措的存在与不存在之间没有统计学上的显著差异(p 0.40)。
COVID-19 大流行可能加速了 AMR 的出现和传播,特别是在医院环境中的革兰氏阴性菌。但是,在使用的 AMR 指标和报告的耐药率方面,研究之间存在相当大的异质性。这些发现强调了在 COVID-19 大流行背景下,需要加强感染预防、抗菌药物管理以及 AMR 监测。